BRPI0914629A2 - compostos e métodos para a modulação de receptores acoplados à proteína g - Google Patents

compostos e métodos para a modulação de receptores acoplados à proteína g

Info

Publication number
BRPI0914629A2
BRPI0914629A2 BRPI0914629A BRPI0914629A BRPI0914629A2 BR PI0914629 A2 BRPI0914629 A2 BR PI0914629A2 BR PI0914629 A BRPI0914629 A BR PI0914629A BR PI0914629 A BRPI0914629 A BR PI0914629A BR PI0914629 A2 BRPI0914629 A2 BR PI0914629A2
Authority
BR
Brazil
Prior art keywords
modulating
protein
compounds
methods
coupled receptors
Prior art date
Application number
BRPI0914629A
Other languages
English (en)
Inventor
Liu Hong
Yang Kunyong
Epple Robert
He Xiaohui
Zhu Xuefeng
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc filed Critical Irm Llc
Publication of BRPI0914629A2 publication Critical patent/BRPI0914629A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0914629A 2008-06-24 2009-06-23 compostos e métodos para a modulação de receptores acoplados à proteína g BRPI0914629A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7509408P 2008-06-24 2008-06-24
PCT/US2009/048265 WO2010008831A2 (en) 2008-06-24 2009-06-23 Compounds and methods for modulating g protein-coupled receptors

Publications (1)

Publication Number Publication Date
BRPI0914629A2 true BRPI0914629A2 (pt) 2019-09-24

Family

ID=41445587

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0914629A BRPI0914629A2 (pt) 2008-06-24 2009-06-23 compostos e métodos para a modulação de receptores acoplados à proteína g

Country Status (11)

Country Link
US (2) US8362050B2 (pt)
EP (1) EP2300442A2 (pt)
JP (1) JP5400878B2 (pt)
KR (1) KR101273765B1 (pt)
CN (1) CN102076670B (pt)
AU (1) AU2009271328B2 (pt)
BR (1) BRPI0914629A2 (pt)
CA (1) CA2729212C (pt)
EA (1) EA019001B1 (pt)
MX (1) MX2010014569A (pt)
WO (1) WO2010008831A2 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3345895B1 (en) 2003-04-11 2019-12-04 PTC Therapeutics, Inc. 1,2,4-oxadiazole benzoic acid compound and its use for nonsense suppression and the treatment of disease
WO2011113947A1 (en) 2010-03-18 2011-09-22 Boehringer Ingelheim International Gmbh Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2014131815A1 (en) * 2013-03-01 2014-09-04 Fundació Hospital Universitari Vall D'hebron - Institut De Recerca Peptides for use in the topical treatment of retinal neurodegenerative disesases, in particular in early stages of diabetic retinopathy and other retinal diseases in which neurodegeneration plays an essential role
US10227360B2 (en) 2014-02-19 2019-03-12 Piramal Enterprises Limited Compounds for use as GPR120 agonists
JP6946001B2 (ja) 2014-03-06 2021-10-06 ピーティーシー セラピューティクス， インコーポレイテッド 薬学的組成物、および１，２，４−オキサジアゾール安息香酸の塩
WO2016008830A1 (de) 2014-07-15 2016-01-21 Bayer Cropscience Aktiengesellschaft Aryl-triazolyl-pyridine als schädlingsbekämpfungsmittel
US10273230B2 (en) 2014-07-25 2019-04-30 Piramal Enterprises Limited Substituted phenyl alkanoic acid compounds as GPR120 agonists and uses thereof
WO2016038540A1 (en) 2014-09-11 2016-03-17 Piramal Enterprises Limited Fused heterocyclic compounds as gpr120 agonists
CA2970011C (en) * 2014-12-24 2021-08-03 Lg Chem, Ltd. Biaryl derivative as gpr120 agonist
CA2974060C (en) 2015-02-05 2022-08-30 Piramal Enterprises Limited Compounds containing carbon-carbon linker as gpr120 agonists
HK1251965A1 (zh) 2015-10-30 2019-05-10 Ptc医疗公司 用於治疗癫痫的方法
EP3416726A4 (en) * 2016-02-17 2019-08-28 Children's Medical Center Corporation FFA1 (GPR40) AS A THERAPEUTIC GOAL FOR NERVENANGIOGENIC DISEASES OR FUNCTIONAL DISORDERS
WO2017165139A1 (en) * 2016-03-25 2017-09-28 St. Jude Children's Research Hospital 1,4,5-substituted 1,2,3-triazole analogues as antagonists of the pregnane x receptor
SG10202001787QA (en) 2016-06-02 2020-04-29 Abbvie Inc Glucocorticoid receptor agonist and immunoconjugates thereof
CN106279057B (zh) * 2016-08-15 2022-04-15 广州明药科技有限公司 Ataluren的合成方法
US12411144B2 (en) * 2017-03-22 2025-09-09 Children's Hospital Medical Center Compositions and methods for treatment of lung function
CA3082356A1 (en) 2017-12-01 2019-06-06 Abbvie Inc. Glucocorticoid receptor agonist and immunoconjugates thereof
US20210163425A1 (en) 2017-12-20 2021-06-03 Gyeonggido Business & Science Accelerator Triazole derivative and use thereof
CA3148831A1 (en) * 2019-07-26 2021-02-04 Pedram HAMRAH A dermal patch for transdermal administration of ghrelin pathway blocker
CN113754541B (zh) * 2020-06-02 2025-01-03 深圳湾实验室 靶向eb病毒核抗原蛋白的小分子抑制剂、制备方法及其应用
JPWO2022168962A1 (pt) * 2021-02-04 2022-08-11
EP4511361A1 (en) * 2022-04-21 2025-02-26 Virginia Commonwealth University Nlrp3 inflammasome inhibitors and compositions and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU497898B2 (en) * 1975-01-10 1979-01-18 Commonwealth Scientific And Industrial Research Organisation Plant growth regulating method and composition for use therein
US4166732A (en) * 1977-05-12 1979-09-04 Monsanto Company Oxadiazol-5-yl-benzoates
DE2910861A1 (de) * 1979-03-20 1980-10-02 Basf Ag Reaktivfarbstoffe
HU228151B1 (en) * 1994-10-07 2012-12-28 Astellas Pharma Inc Cyclic hexapeptides
WO1997003967A1 (en) * 1995-07-22 1997-02-06 Rhone-Poulenc Rorer Limited Substituted aromatic compounds and their pharmaceutical use
DE19620041A1 (de) * 1996-05-17 1998-01-29 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
AUPP999799A0 (en) * 1999-04-27 1999-05-20 Fujisawa Pharmaceutical Co., Ltd. New compound
JP2001316378A (ja) * 2000-04-28 2001-11-13 Takeda Chem Ind Ltd ベンズアミド誘導体およびその用途
US7223791B2 (en) * 2001-06-26 2007-05-29 Takeda Pharmaceutical Company Limited Function regulator for retinoid relative receptor
JP2005162612A (ja) * 2002-01-09 2005-06-23 Ajinomoto Co Inc アシルスルホンアミド誘導体
CA2474322A1 (en) * 2002-01-25 2003-07-31 Kylix Pharmaceuticals B.V. 4(hetero-) aryl substituted (thia-/oxa-/pyra) zoles for inhibition of tie-2
GB0303503D0 (en) * 2003-02-14 2003-03-19 Novartis Ag Organic compounds
EP3345895B1 (en) * 2003-04-11 2019-12-04 PTC Therapeutics, Inc. 1,2,4-oxadiazole benzoic acid compound and its use for nonsense suppression and the treatment of disease
EP1628666B1 (en) * 2003-05-14 2015-09-23 NeuroGenetic Pharmaceuticals, Inc. Compouds and uses thereof in modulating amyloid beta
EP1688138A4 (en) * 2003-11-26 2008-01-16 Takeda Pharmaceutical AGENT FOR REGULATING THE FUNCTION OF A RECEIVER
WO2005108370A1 (ja) * 2004-04-16 2005-11-17 Ajinomoto Co., Inc. ベンゼン化合物
WO2006044456A1 (en) * 2004-10-13 2006-04-27 Ptc Therapeutics, Inc. Compounds for nonsense suppression, and methods for their use
KR20080019213A (ko) * 2005-05-09 2008-03-03 아칠리온 파르마세우티칼스 인코포레이티드 티아졸 화합물 및 그 사용방법
US7947707B2 (en) * 2005-10-07 2011-05-24 Kissei Pharmaceutical Co., Ltd. Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same
JP2008001690A (ja) 2006-05-26 2008-01-10 Pharma Frontier Kk Ｇタンパク質共役型レセプターの作動剤および医薬
AU2007326395B2 (en) * 2006-12-01 2012-10-11 Msd K.K. Novel phenyl-isoxazol-3-ol derivative
JP2008195625A (ja) 2007-02-08 2008-08-28 Pharma Frontier Kk Ｇ蛋白質共役型レセプター抑制剤および医薬
KR20090113382A (ko) * 2007-02-22 2009-10-30 아이알엠 엘엘씨 Ｇ 단백질-커플링된 수용체의 조절제로서의 티아졸 유도체
JP5175866B2 (ja) * 2007-02-22 2013-04-03 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｇタンパク質共役受容体を調節するための化合物および方法
WO2008139879A1 (ja) * 2007-04-26 2008-11-20 Pharmafrontier, Co., Ltd. Ｇ蛋白質共役型レセプター抑制剤および医薬
US8318781B2 (en) * 2007-04-26 2012-11-27 Japan Science And Technology Agency G-protein-conjugated receptor agonist
JPWO2009147990A1 (ja) * 2008-06-02 2011-10-27 Ｍｓｄ株式会社 新規イソオキサゾール誘導体
AR074760A1 (es) * 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.

Also Published As

Publication number Publication date
KR20110022693A (ko) 2011-03-07
MX2010014569A (es) 2011-03-29
CA2729212A1 (en) 2010-01-21
CN102076670B (zh) 2013-05-22
EP2300442A2 (en) 2011-03-30
AU2009271328B2 (en) 2012-09-06
US8362050B2 (en) 2013-01-29
EA019001B1 (ru) 2013-12-30
KR101273765B1 (ko) 2013-06-12
WO2010008831A3 (en) 2010-09-30
US20110172278A1 (en) 2011-07-14
JP5400878B2 (ja) 2014-01-29
AU2009271328A1 (en) 2010-01-21
WO2010008831A2 (en) 2010-01-21
US20130096165A1 (en) 2013-04-18
EA201100062A1 (ru) 2011-08-30
CN102076670A (zh) 2011-05-25
JP2011525534A (ja) 2011-09-22
CA2729212C (en) 2014-04-01

Similar Documents

Publication Publication Date Title
BRPI0914629A2 (pt) compostos e métodos para a modulação de receptores acoplados à proteína g
LTPA2020513I1 (lt) S1P receptoriaus agonisto dozavimas
BRPI0910564A2 (pt) fecho para um sub equipamento
ATE524460T1 (de) Pyridon-gpr119-g-protein-gekoppelte rezeptoragonisten
BRPI0813498A2 (pt) Aparelho e métodos para fixar um prendedor
BRPI0916184A2 (pt) método para a formação de um equipamento de iluminação e equipamento de iluminação
BRPI0906906A2 (pt) Método para preparar um composto e composto
DK3409274T3 (da) Doseringsskema for en s1p-receptoragonist
BRPI0921138A2 (pt) montagem para uma ferramenta substituível
BRPI0921020A2 (pt) dispositivo para cobertura de uma superfície
NO20073434L (no) Innretning tilpasset for en undersjøisk applikasjon
BRPI0919872A2 (pt) dispositivo para a fixação de imãs
BRPI0919682A2 (pt) mecanismo de fixação para um dispensador
BRPI0811075A2 (pt) Mecanismo de ajuste para um guincho
EP2273140A4 (en) DEVICE WITH SEALS
BRPI0815574A2 (pt) Método e equipamento para gerar um cryptosync
BRPI0822061A2 (pt) Moduladores do receptor canabinoide
BRPI0812186A2 (pt) Método de rastreio para compostos que reduzem a tensão re
BRPI0917375A2 (pt) composicoes e metodos para fornecimento de um beneficio
BRPI0811694A2 (pt) Dispositivo de conexão para conexão destacável a um componente
BRPI0807650A2 (pt) Fecho rosqueado para conexão rosqueada
DE602007008589D1 (de) Pyridooxazepin-progesteronrezeptor-modulatoren
ES1064720Y (es) Guia para persiana
ES1069185Y (es) Premarco para cerramientos
ES1065835Y (es) Caperuza para cetreria

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.